DV
Dividend Vision

BDRX — Biodexa Pharmaceticals

Biodexa Pharmaceticals (BDRX)

Total return is -100.0% over the past 10.7 years, 444.6 points behind SPY at 344.6%. Its deepest 1-year drawdown was 97.6%.

Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and rare brain cancers, with lead candidate Tolimidone in Phase II trials and additional programs including MTX110 and MTX240 in earlier stages. The company does not currently distribute dividends. Biodexa appeals primarily to investors seeking exposure to early-stage drug development, particularly those with higher risk tolerance and a longer investment horizon, rather than income-focused investors.

BDRX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/07/2015
Last close
$1.52
Market cap
$1,925,660
Average volume
10400.0
Payment date
03/03/2020
Beta
1.209
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.30